P
Piero Dalerba
Researcher at Columbia University
Publications - 60
Citations - 16901
Piero Dalerba is an academic researcher from Columbia University. The author has contributed to research in topics: Stem cell & Cancer stem cell. The author has an hindex of 30, co-authored 54 publications receiving 15541 citations. Previous affiliations of Piero Dalerba include Istituto Superiore di Sanità & Stanford University.
Papers
More filters
Journal ArticleDOI
Identification of Pancreatic Cancer Stem Cells
Chenwei Li,David G. Heidt,Piero Dalerba,Charles F. Burant,Lanjing Zhang,Volkan Adsay,Max S. Wicha,Michael F. Clarke,Diane M. Simeone +8 more
TL;DR: This work identified a highly tumorigenic subpopulation of pancreatic cancer cells expressing the cell surface markers CD44, CD24, and epithelial-specific antigen (ESA) that showed the stem cell properties of self-renewal, the ability to produce differentiated progeny, and increased expression of the developmental signaling molecule sonic hedgehog.
Journal ArticleDOI
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma
Mark E. Prince,Ranjiv Sivanandan,Andrew J. Kaczorowski,Gregory T. Wolf,Michael J. Kaplan,Piero Dalerba,Irving L. Weissman,Michael F. Clarke,Laurie Ailles +8 more
TL;DR: Data demonstrate that cells within the CD44+ population of human HNSCC possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation and form unique histological microdomains that may aid in cancer diagnosis.
Journal ArticleDOI
Phenotypic characterization of human colorectal cancer stem cells
Piero Dalerba,Scott J. Dylla,In-Kyung Park,Rui Liu,Xinhao Wang,Robert W. Cho,Timothy Hoey,Austin L. Gurney,Emina Huang,Diane M. Simeone,Andrew A. Shelton,Giorgio Parmiani,Chiara Castelli,Michael F. Clarke +13 more
TL;DR: The results validate the stem cell working model in human CRC and provide a highly robust surface marker profile for CRC stem cell isolation.
Journal ArticleDOI
Cancer Stem Cells: Models and Concepts
TL;DR: The biological basis and the therapeutic implications of the stem cell model of cancer, first developed in human myeloid leukemias, is reviewed, which is today being extended to solid tumors, such as breast and brain cancer.
Journal ArticleDOI
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham,Jens Peter Volkmer,Andrew J. Gentles,Debashis Sahoo,Piero Dalerba,Siddhartha Mitra,Jian Wang,Humberto Contreras-Trujillo,Robin Martin,Justin D. Cohen,Patricia Lovelace,Ferenc A. Scheeren,Mark P. Chao,Kipp Weiskopf,Chad Tang,Anne Kathrin Volkmer,Tejaswitha J. Naik,Theresa A. Storm,Adriane Mosley,Badreddin Edris,Seraina Schmid,Chris K. Sun,Mei-Sze Chua,Oihana Murillo,Pradeep S. Rajendran,Adriel C. Cha,Robert K. Chin,Dongkyoon Kim,Maddalena Adorno,Tal Raveh,Diane Tseng,Siddhartha Jaiswal,Per Øyvind Enger,Gary K. Steinberg,Gordon Li,Samuel So,Ravindra Majeti,Griffith R. Harsh,Matt De Van Rijn,Nelson N.H. Teng,John B. Sunwoo,Ash A. Alizadeh,Michael F. Clarke,Irving L. Weissman +43 more
TL;DR: All human solid tumor cells require CD47 expression to suppress phagocytic innate immune surveillance and elimination, showing that CD47 is a commonly expressed molecule on all cancers, its function to blockphagocytosis is known, and blockade of its function leads to tumor cell phagcytosis and elimination.